Guselkumab Shows Psoriasis Benefit in Darker Skin Tones - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

  • By

  • Andrea Surnit

  • May 14, 2026

  • 3 min

Share

  • 1

    Guselkumab significantly improved skin clearance in patients with darker skin tones suffering from moderate to severe plaque psoriasis.

  • 2

    In a trial, 74% of patients receiving guselkumab achieved clear or almost clear skin at week 16, compared to 0% in the placebo group.

  • 3

    The study showed that 57% of guselkumab-treated patients achieved at least 90% improvement in psoriasis severity by week 16.

  • 4

    Patient-reported outcomes, including quality of life and itch scores, improved alongside clinical measures in the guselkumab group.

  • 5

    Adverse events were more common in the guselkumab group, but serious events were rare, indicating a favorable safety profile.

Original Source(s)

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

  • by Andrea Surnit

  • May 14, 2026

Related Content

Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

Spondyloarthritis function varies by sex

Women had greater functional deterioration over 17 years, while permanent work disability did not differ significantly between sexes.